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SUMMARY 1 
Circulating TNF-related apoptosis-inducing ligand (TRAIL) levels are reduced in patients with 2 
cardiovascular disease, and TRAIL gene deletion in mice exacerbates atherosclerosis and 3 
inflammation. How TRAIL protects against atherosclerosis, and why levels are reduced in disease is 4 
unknown. Here, multiple strategies were used to identify the protective source of TRAIL, and its 5 
mechanism(s) of action. Samples from coronary artery disease patients and bone-marrow 6 
transplantation experiments in mice lacking TRAIL revealed monocytes/macrophages as the main 7 
protective source. Accordingly, deletion of TRAIL caused a more inflammatory macrophage with 8 
reduced migration, displaying impaired reverse cholesterol efflux and efferocytosis. Furthermore, IL-9 
18, commonly increased in plasma of patients with cardiovascular disease, negatively regulated 10 
TRAIL transcription and gene expression, revealing an IL-18-TRAIL axis. These findings 11 
demonstrate that TRAIL is protective of atherosclerosis by modulating monocyte/macrophage 12 
phenotype and function. Manipulating TRAIL levels in these cells highlights a different therapeutic 13 
avenue in the treatment of cardiovascular disease. 14 
  15 
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INTRODUCTION 1 
Despite improvements in treatment, cardiovascular disease (CVD) remains the leading cause of death 2 
world-wide. The main cause is atherosclerosis, the pathological process underlying stroke, coronary 3 
artery disease (CAD) and peripheral vascular disease. Cells of the myeloid lineage, particularly 4 
monocyte/macrophages, play a pivotal role in atherogenesis, which is triggered by an inflammatory 5 
response to lipoproteins that are modified in the vessel wall. Here, innate responses initiate the 6 
recruitment, homing, migration and differentiation of monocytes into macrophages, where they 7 
orchestrate a plethora of functions including phagocytosis, efferocytosis, proliferation, migration, 8 
secretion of inflammatory molecules (e.g. TNF-α), production of resolving molecules (e.g. IL-10), 9 
and cell death. In mature lesions, failure of macrophage resolution mechanisms and the subsequent 10 
increased immune response may underlie processes that exacerbate disease (Tabas, 2010).  11 
 12 
TNF-related apoptosis-inducing ligand (TRAIL) was originally identified as a cancer-killing cytokine, 13 
but over the last 10 years it has become clear that TRAIL has pleiotropic functions beyond killing, 14 
and can modulate multiple cellular processes including proliferation, migration and differentiation 15 
(Harith et al., 2013; Kavurma and Bennett, 2008; Kavurma et al., 2008b; Manuneedhi Cholan et al., 16 
2017). Our particular interest is its role in CVD. In humans, low plasma TRAIL levels independently 17 
predict cardiovascular events and mortality (Volpato et al., 2011), and TRAIL is reduced in the 18 
circulation of CVD patients (Schoppet et al., 2006), suggesting a protective role. The recent 19 
identification of 11 loss-of-function TRAIL single nucleotide polymorphisms (SNPs) that confer 20 
increased risk of carotid artery atherosclerosis supports this view (Pott et al., 2017). Importantly, we 21 
and others identified TRAIL’s non-apoptotic functions in the vasculature, including in neointimal 22 
thickening, angiogenesis and peripheral vascular disease, and in advanced atherosclerosis (Chan et al., 23 
2010; Di Bartolo et al., 2013; Di Bartolo et al., 2015; Di Bartolo et al., 2011; Kavurma et al., 2008a; 24 
Secchiero et al., 2006; Secchiero et al., 2004a). Our atherosclerotic murine models lacking TRAIL 25 
corroborate the human association studies. For example, high fat diet (HFD)-fed Trail-/-Apoe-/- mice 26 
exhibited 150% larger plaques than Apoe-/- mice (Di Bartolo et al., 2011).  Intriguingly, these mice 27 
had significantly more monocyte/macrophage-rich plaques, but also increased monocyte/macrophage 28 
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numbers in kidney (Cartland et al., 2014) and pancreata (Di Bartolo et al., 2011), suggesting that 1 
TRAIL may control macrophage accumulation in injured tissues. In contrast to our observations, 2 
TRAIL administration to diabetic Apoe-/- mice attenuated atherosclerosis, in part, by inducing 3 
macrophage death (Secchiero et al., 2006). Thus, the role of TRAIL in monocyte/macrophage 4 
function is unclear. Here we examined samples from patients with CAD and several murine models of 5 
atherosclerosis, as well as monocyte/macrophages in vitro.  We identified an iNOShiTRAIL+ 6 
macrophage population that appeared critical in resolving atherosclerosis. Furthermore, we describe a 7 
unique anti-inflammatory pathway, the IL-18-TRAIL axis, in patients with CAD. These findings 8 
suggest that TRAIL is critical in modulating atherogenesis and have wider implications in 9 
mechanisms regulating inflammation. 10 
 11 
 12 
RESULTS 13 
 14 
Circulating TRAIL is reduced in CAD patients and associates with reduced monocyte TRAIL 15 
mRNA. 16 
To assess local coronary production of TRAIL, we measured plasma concentrations in blood sampled 17 
from 3 sites around the heart, collected from control, stable and unstable CAD patients. Regardless of 18 
sampling site, TRAIL was significantly lower in plasma from CAD patients, ~45% less than control 19 
levels (Figure 1a). In contrast, TNF-α (Figure 1b), a cytokine with high sequence homology to 20 
TRAIL, was similar in all samples. No differences were found in the TRAIL arterial-coronary sinus 21 
gradient (Figure 1c), indicating that the source of TRAIL was systemic rather than directly from the 22 
heart. Plasma from a second cohort of patients with unstable CAD also contained markedly less 23 
TRAIL at ~70% less than control levels (Figure 1d). Importantly, TRAIL mRNA in monocytes from 24 
the same individuals was also strikingly reduced (~70%; Figure 1e), implicating these cells as a major 25 
source of TRAIL in healthy circulation, that may be compromised in CAD patients. 26 
 27 
TRAIL expressing monocyte/macrophages protect against atherosclerosis. 28 
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Wildtype mice do not develop significant atherosclerosis without the disruption of genes critical in 1 
cholesterol metabolism. Apolipoprotein E (ApoE) is key in maintaining plasma cholesterol 2 
concentrations. Deletion in mice causes hypercholesterolemia and spontaneous development of 3 
atherosclerotic lesions that are accelerated by HFD feeding (Meir and Leitersdorf, 2004). We showed 4 
that TRAIL deletion in Apoe-/- mice (Trail-/-Apoe-/-) exacerbated plasma cholesterol levels, and 5 
macrophage-rich plaques were larger and more frequent than in Apoe-/- mice fed a HFD (Di Bartolo et 6 
al., 2011). These findings indicated a protective role for TRAIL.  7 
 8 
Monocytes originate in bone marrow, and because they were a significant source of TRAIL in people 9 
(Figure 1), we predicted that TRAIL-expressing (TRAIL+) bone marrow, afforded protection in 10 
atherosclerosis. To investigate this, we examined two sources using bone marrow chimeras: TRAIL 11 
expressed only in the bone marrow (BM-TRAIL) and TRAIL expressed everywhere except the bone 12 
marrow (parenchymal-TRAIL). Results were compared to mice with no TRAIL in bone marrow or 13 
parenchyma (null-TRAIL). The bone marrow chimera study design is illustrated in Figure 2a. 14 
Brachiocephalic arteries of BM-TRAIL mice had significantly reduced atherosclerotic lesion size 15 
compared to the null- and parenchymal-TRAIL lesions which had ~50% more atherosclerosis (Figure 16 
2b). Body weight and plasma chemistries, including total cholesterol, triglycerides, glucose and 17 
insulin were similar between groups (Table 1). Interestingly, atherosclerotic lesions from BM-TRAIL 18 
mice were of similar size to those in Trail-/-Apoe-/- samples harvested after 5-8 w HFD (Figure 2c), 19 
suggesting that TRAIL expressed in the bone marrow slows atherogenesis. Depletion of macrophages 20 
in HFD-fed Trail-/-Apoe-/- using clodronate liposomes dramatically reduced atherosclerotic plaque size 21 
(Figure 2d), confirming that a significant number of cells in the plaque are of monocyte/macrophage 22 
origin. Immunohistochemical assessment showed significantly lower numbers of Mac3+ macrophages 23 
in BM-TRAIL plaque compared to lesions from null- or parenchymal-TRAIL mice (Figure 2e). The 24 
reduction in lesion size by TRAIL+ monocyte/macrophages was even more remarkable, given that 25 
TRAIL mRNA expression from BM-TRAIL aortae was ~50-fold less than parenchymal-TRAIL 26 
samples (Figure 2f); TRAIL was undetectable in aortae from null-TRAIL mice (Figure 2f). In 27 
agreement with this, plasma from BM-TRAIL mice had significantly reduced TRAIL concentrations, 28 
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~2.5-fold less than in plasma from parenchymal-TRAIL mice (Table 1). By combining plasma 1 
TRAIL concentrations from BM-TRAIL and parenchymal-TRAIL mice (Table 1), we estimated that 2 
~30% of plasma TRAIL was derived from cells originating in the bone marrow. Collectively, these 3 
findings indicate that BM cells are a protective source of TRAIL, and that TRAIL+ 4 
monocyte/macrophages markedly reduce atherosclerosis. 5 
 6 
To confirm that TRAIL+ monocyte/macrophages could also reduce inflammation and macrophage 7 
numbers in other tissues, we examined pancreata from bone marrow chimera mice. There was ~50% 8 
less Mac3+ immunoreactivity in pancreata from BM-TRAIL mice compared to null-TRAIL pancreatic 9 
islets (Figure S1a). Macrophage accumulation was similarly reduced in parenchymal-TRAIL islets 10 
(Figure S1a). These indicate that TRAIL expression reduced monocyte/macrophage content 11 
regardless of its source. However, while reconstitution with TRAIL+ monocyte/macrophages reduced 12 
atherosclerosis in BM-TRAIL mice, this did not affect glucose handling. Glucose tolerance testing 13 
(GTT) indicated that parenchymal-TRAIL mice had improved glucose clearance compared to null- or 14 
BM-TRAIL mice (Figure S1b) associating with significantly reduced active caspase-3 staining 15 
(Figure S1c). Active caspase-3 immunoreactivity was also reduced in BM-TRAIL islets, although this 16 
did not reach significance (Figure S1c). No differences in insulin tolerance, insulin expression, islet 17 
area or islet number between groups were observed (Figure S1d-g). These findings suggest that 18 
TRAIL+ monocyte/macrophages appear to have functions distinct from TRAIL+ parenchymal cells, 19 
highlighting tissue and cell-specific responses.  20 
 21 
Macrophages lacking TRAIL have impaired cholesterol metabolism. 22 
Atherosclerosis associates with expanded hematopoietic stem cell numbers (Murphy et al., 2011). 23 
Because HFD Trail-/-Apoe-/- mice develop larger plaques than Apoe-/- (Di Bartolo et al., 2011), and 24 
TRAIL+ monocyte/macrophage reconstitution attenuated atherosclerosis with concomitantly less 25 
macrophage accumulation in vascular tissues (Figure 2), we assessed whether inherent differences in 26 
hematopoietic stem cell numbers were associated with TRAIL deletion. No differences in 27 
hematopoietic stem cells, common myeloid, lymphoid, erythroid or granulocyte progenitors, or 28 
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monocyte precursors in bone marrow from Apoe-/- (TRAIL+ve) vs. Trail-/-Apoe-/- (TRAIL-ve) mice 1 
were apparent (Figure S2), suggesting that the changes we observed in Figure 2 occurred once the 2 
cells had left the bone marrow and differentiated.  3 
 4 
Cholesterol accumulation in macrophages is a defining feature of atherosclerosis, and homeostasis is 5 
maintained by cholesterol uptake and export (Jessup and Kritharides, 2008). Uptake can occur via 6 
scavenger receptors CD36 and SRA, and by phagocytosis of aggregated LDL, whereas cholesterol 7 
export occurs primarily via reverse cholesterol transporters ABCA1 and ABCG1 (Du et al., 2015; Out 8 
et al., 2008). Interestingly, macrophages differentiated from Apoe-/- mice (TRAIL+ve) and loaded 9 
with acetylated LDL (acLDL) to recapitulate an atherosclerotic environment, had significantly 10 
reduced TRAIL mRNA expression (Figure 3a). We found that TRAIL-ve (Trail-/-Apoe-/-) 11 
macrophages had no change in CD36 or SRA mRNA (Figure 3b), or phagocytic ability (Figure 3c). 12 
On the other hand, ABCA1 and ABCG1 mRNA expression was significantly reduced (Figure 3d), 13 
and TRAIL-ve macrophages had a diminished capacity to export cholesterol compared to TRAIL+ve 14 
macrophages as evidenced by reduced cholesterol efflux to Apo-A1 (Figure 3e). These findings 15 
indicate that TRAIL deletion in macrophages impairs reverse cholesterol transport, making 16 
macrophages more lipid laden. 17 
 18 
Macrophages lacking TRAIL exacerbate inflammation and impair efferocytosis. 19 
Activated monocyte/macrophages express and secrete inflammatory cytokines. The mechanisms 20 
whereby TRAIL may modulate inflammation in the vessel wall, and the expression of inflammatory 21 
cytokines involved in the progression of atherosclerosis was measured. Consistent with accelerated 22 
atherosclerosis in mice with TRAIL deletion (Figure 2b-c), TRAIL-ve macrophages had > 2-fold 23 
higher CCL-2 mRNA (Figure 4a), a potent monocyte chemoattractant implicated in atherosclerosis 24 
progression (Aiello et al., 1999; Gu et al., 1998). TRAIL-ve macrophages also had a more reactive, 25 
inflammatory phenotype following LPS challenge, with significantly higher TNF-α, IL-1β, and IL-6 26 
mRNA expression than TRAIL+ve macrophages (Figure 4b). Correspondingly, anti-inflammatory IL-27 
10 mRNA was significantly reduced with TRAIL deletion (Figure 4b). Similarly, acLDL-loaded 28 
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TRAIL-ve macrophages expressed more IL-1β and IL-6, but not TNFα (Figure 4c). CD11b 1 
expression is reduced on macrophages involved in the resolution of inflammation (Ortega-Gomez et 2 
al., 2013). Importantly, we show that CD11b expression on TRAIL-ve macrophages was elevated, 3 
both at the level of mRNA and protein (Figure 4c, d). Collectively, these findings imply that TRAIL 4 
deletion promotes an inflammatory macrophage.  5 
 6 
Apoptosis is triggered by inflammation in atherosclerotic lesions and macrophage apoptosis under 7 
these circumstances can be detrimental if not coupled with effective efferocytosis (Kavurma et al., 8 
2017a). We next examined cell viability, apoptosis and expression of genes important in efferocytosis. 9 
Viability of TRAIL+ve and TRAIL-ve macrophages was similar (Figure 4f), and levels of apoptosis 10 
low, with no difference over 21 d in culture (Figure 4g).  In contrast, MerTK mRNA was ~50% less 11 
in TRAIL-ve macrophages (Figure 4h), associating with a significant reduction in efferocytosis 12 
(Figure 4i). Of note, MerTK is a transmembrane protein, mutation of which disrupts signaling, 13 
resulting in dysfunctional efferocytosis in Apoe-/- mice (Thorp et al., 2008). TRAIL-ve macrophages 14 
also had significantly reduced migration to CCL-19 (Figure 4j), a chemokine implicated in 15 
macrophage egress and plaque regression (Feig, 2014). These findings suggest that macrophages 16 
lacking TRAIL may be defective in removing dead/dying cells and modulating tissue repair. 17 
 18 
TRAIL deletion effects the nitric oxide synthase pathway. 19 
The nitric oxide (NO) pathway is critical for maintenance of cardiovascular homeostasis and 20 
contributes to maintaining an anti-thrombotic, anti-inflammatory and anti-atherogenic state within the 21 
vessel wall. Macrophages produce and respond to NO, and the inducible nitric oxide synthase (iNOS) 22 
pathway catalyzes production of NO and citrulline from L-arginine. We focused on this because we 23 
reported that physiologically-relevant concentrations of TRAIL stimulate phosphorylation of 24 
endothelial-derived NOS (eNOS), and increased intracellular NO concentrations in human endothelial 25 
cells, promoting their proliferation, migration and differentiation (Cartland et al., 2016; Di Bartolo et 26 
al., 2015). Plasma nitrate/nitrite levels are an indicator of NO production in vivo. Importantly these 27 
were reduced in samples from HFD Trail-/-Apoe-/- mice (Figure 5a). Furthermore, arginine and 28 
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citrulline levels were significantly less in Trail-/- plasma, although levels of the endogenous NOS 1 
inhibitor, asymmetric dimethylarginine (ADMA), remained unchanged (Table 2). Plasma from BM-2 
TRAIL mice also had significantly less citrulline compared to null- or parenchymal TRAIL (Figure 3 
5b), whereas plasma arginine levels were similar between groups (data not shown).   4 
 5 
We performed transcriptome analysis of aortic tissues from Trail-/- and wildtype mice and found 845 6 
genes were differentially expressed. Hierarchical clustering of these demonstrated opposing gene 7 
expression patterns, and gene ontology analysis indicated enrichment for biological processes (Figure 8 
5c-d). Interestingly, cysteine/methionine metabolism was identified as a top pathway altered by 9 
TRAIL deletion (enrichment score = 3.57; p=0.028), and cysteine levels in plasma from these mice 10 
were ~45% less than in wildtype mice, whereas methionine concentrations did not change (Table 2). 11 
These findings are significant as cysteine is important for NOS function (Forstermann and Sessa, 12 
2012). 13 
 14 
iNOS is expressed by macrophages, and TRAIL-ve macrophages had significantly less iNOS 15 
expression constitutively, following LPS, or acLDL stimulation (Figure 5e-g). iNOS mRNA was 16 
~40% less in aortic tissue from Trail-/- compared to wildtype mice (Figure 5h) and was significantly 17 
reduced to almost baseline (by ~90%), in samples from HFD Trail-/-Apoe-/- mice (Figure 5i). 18 
Importantly, iNOS mRNA in aortae from reconstituted BM-TRAIL mice was restored when 19 
compared with null- and parenchymal-TRAIL samples (Figure 5j). Thus, TRAIL appears integral to 20 
iNOS expression in macrophages and iNOShiTRAIL+ macrophages may help to maintain levels of 21 
arginine and cysteine necessary to attenuate atherosclerosis.  22 
 23 
IL-18 negatively regulates TRAIL expression in monocytes. 24 
We have identified an iNOShiTRAIL+ macrophage population that appears critical in moderating 25 
atherosclerosis. Mechanisms whereby TRAIL is reduced in monocytes from people with CAD are 26 
unknown. We previously showed that CAD patients had elevated plasma IL-18, IL-1β and IL-6 27 
concentrations (Martinez et al., 2015). Here we show a significant inverse correlation between plasma 28 
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TRAIL and IL-18 in these patient samples (R2=0.2344, p=0.0105), but not between TRAIL and IL-1 
1β, or IL-6 (Figure 6a), suggesting an IL-18-TRAIL axis. In fact, IL-18 mRNA was significantly 2 
increased in aortic tissues from atherosclerotic Trail-/-Apoe-/- mice (Figure 6b). To confirm a direct 3 
relationship, human monocytes were incubated with recombinant IL-18 and TRAIL mRNA 4 
measured. Importantly, IL-18 significantly repressed TRAIL mRNA expression by ~60%, without 5 
affecting TNF-α (Figure 6c-d). We examined the mechanism of this repression further and measured 6 
the direct effect of IL-18 on NFκB p65 and Sp1 expression, two transcription factors that we showed 7 
control TRAIL transcriptional activity in vascular cells by combinatorial interaction (Chan et al., 8 
2010; Reddy et al., 2010). IL-18 reduced NFκB p65 mRNA expression in human monocytes by 9 
~50%, without affecting Sp1 levels (Figure 6e, f). IL-18 also reduced NFκB p65 activity, because the 10 
phosphorylated form (p-NFκB p65) was significantly reduced, ~50% (Figure 6g). Importantly, NFκB 11 
enrichment on the endogenous TRAIL promoter was significantly reduced in healthy monocytes 12 
exposed to IL-18, whereas Sp1 enrichment remained unaltered (Figure 6h). These findings indicate 13 
that IL-18 moderates TRAIL transcription by altering NFκB binding activity. This mechanism may 14 
account for the reduced systemic TRAIL levels observed in CAD. 15 
 16 
DISCUSSION 17 
Despite aggressive risk factor management, many CVD patients suffer heart attacks, highlighting the 18 
need for new biomarkers, prognostic factors and therapies. Here, we have identified that monocytes 19 
from healthy human donors are a significant source of TRAIL, whereas monocytes from patients with 20 
CAD express significantly less TRAIL mRNA, concomitant with reduced plasma levels. In mice with 21 
severe disease, reconstitution of TRAIL+ monocyte/macrophages markedly attenuated atherosclerosis 22 
by reducing macrophage accumulation and increasing iNOS levels. Furthermore, we identified IL-18 23 
as a negative regulator of TRAIL transcription in human monocytes. The recent identification of 24 
TRAIL SNPs associating with atherosclerosis (Pott et al., 2017), further underpins the biological 25 
significance of our findings. Circulating TRAIL levels, and/or TRAIL/IL-18 ratios, may predict an 26 
individual’s risk of developing CVD. Our work also highlights the potential for targeting 27 
monocyte/macrophage-derived TRAIL in atherogenesis for the treatment of CVD.   28 
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 1 
Much of TRAIL biology has focused on its ability to kill cancer cells. However, low TRAIL 2 
concentrations positively associate with CVD in people (Schoppet et al., 2006), suggesting a role that 3 
goes beyond that of killing. Indeed, non-apoptotic functions, including stimulation of cell survival, 4 
proliferation and migration, particularly in vascular cells  (Azahri et al., 2012; Cartland et al., 2014; 5 
Cartland et al., 2017; Chan et al., 2010; Di Bartolo et al., 2015; Harith et al., 2015; Kavurma et al., 6 
2008a; Secchiero et al., 2004a; Secchiero et al., 2004b), and even cancer cells (Lancaster et al., 2003; 7 
Secchiero et al., 2005) have been described. However, in CVD, because TRAIL’s cellular source is 8 
unknown, it was unclear why concentrations were reduced, and the direct impact this could have on 9 
pathogenesis. Here we show that monocyte/macrophages represent a significant source of TRAIL in 10 
healthy individuals, which was suppressed in monocytes from CAD patients. Importantly, we 11 
identified IL-18 as a negative regulator of TRAIL expression in these cells. IL-18 is synthesized as an 12 
inactive precursor, expressed constitutively by macrophages and other cells within the vessel wall 13 
(Gerdes et al., 2002; Gracie et al., 2003). This has significant implications because circulating IL-18 14 
levels are increased in CAD patients (Martinez et al., 2015; Robertson et al., 2016), and IL-18 is 15 
linked to atherosclerosis in mice (Elhage et al., 2003; Whitman et al., 2002), with  mature IL-18 16 
secreted primarily from monocyte/macrophages following caspase-1 cleavage (Gerdes et al., 2002; 17 
Gracie et al., 2003). IL-18 can also modulate activity of multiple transcription factors including NFκB 18 
and Sp1 (Reddy et al., 2010), and critically, we showed that IL-18 influenced NFκB binding ability on 19 
the endogenous TRAIL promoter, contributing to suppressed TRAIL transcription. These suggest a 20 
mechanism for reduced TRAIL levels observed in patients with CAD.  21 
 22 
NO is a powerful vasodilator, and plays important roles in inflammation and maintaining vessel tone 23 
(MacMicking et al., 1997). iNOS is generally expressed by proinflammatory macrophages in 24 
atherosclerosis (Moore et al., 2013). We found markedly less iNOS mRNA in Trail-/-Apoe-/- 25 
macrophages, and in vascular tissue from Trail-/- and Trail-/-Apoe-/- mice, particularly from the latter 26 
that were fed a HFD, and manifested a strong atherosclerotic phenotype. Importantly, reconstitution 27 
of Trail-/-Apoe-/- mice with bone marrow expressing TRAIL markedly increased aortic iNOS mRNA, 28 
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and concentrations of its metabolite citrulline were significantly less than in null- or parenchymal-1 
TRAIL expressing samples. Thus, TRAIL+ monocyte/macrophages may contribute to vascular 2 
protection by increasing iNOS gene expression, thereby facilitating NO production. Our findings, and 3 
those of Lu et al. (2015), challenge the concept of iNOS as a marker of inflammatory macrophages. 4 
For example, macrophages from iNOS-/- mice showed increased polarization to an inflammatory 5 
macrophage (Lu et al., 2015). NO generated by iNOS also reduced leukocyte-endothelium 6 
interactions (Hickey et al., 1997). Furthermore, IL-18 modulates iNOS via NFκB-dependent 7 
mechanisms (Jablonska et al., 2006), however an interesting control mechanism worthy of 8 
consideration in this context, is the prevention of IL-18 release from macrophages by NO-mediated 9 
suppression of caspase-1 (Kim et al., 2002) . Taken together, our findings suggest that TRAIL 10 
regulates the iNOS pathway in macrophages, and it is tantalizing to speculate that TRAIL-induced 11 
iNOS attenuates their infiltration via NO to reduce atherogenesis. Notably, these may also be 12 
influenced by IL-18.  13 
 14 
In chronic CVD, macrophages change from a resolving to a pro-inflammatory phenotype, propagating 15 
the inflammatory milieu of the plaque (reviewed in (Kavurma et al., 2017b)). Here we propose 16 
TRAIL as a player in macrophage biology, protecting against atherosclerosis and macrophage 17 
accumulation, and provide mechanistic insights into monocyte/macrophage function(s) in CAD.  We 18 
propose the reduced TRAIL expression in monocyte/macrophages from CAD patients may impair 19 
these processes i.e. by promoting a more inflammatory monocyte/macrophage, increasing cellular 20 
cholesterol accumulation in lesions, aggravated by the inability of these cells to egress, or 21 
efferocytose, which collectively result in severe atherosclerosis. Interestingly, TRAIL+ 22 
monocyte/macrophage reconstitution also reduced inflammation in pancreata. Thus, impairment of 23 
macrophage processes as observed in atheroma, may also be evident in pancreatic islets. Indeed, 24 
during islet inflammation, proinflammatory macrophages contribute to β-cell dysfunction in diabetes, 25 
yet resolving macrophages are essential for physiological β-cell proliferation and survival (Eguchi 26 
and Nagai, 2017). Whether TRAIL’s pro-resolving function(s) in macrophages affect β-cell function 27 
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is unclear. Interestingly, however, TRAIL+ parenchymal cells also inhibited MAC3+ cell 1 
accumulation to the same degree as reconstitution of TRAIL+ monocyte/macrophages. TRAIL-2 
expressing parenchymal cells also improved whole-body glucose clearance in response to a glucose 3 
tolerance test. These findings suggest two things: that when monocyte/macrophage accumulation is 4 
the driver of disease, as in atherosclerosis, TRAIL+ monocyte macrophages are critical in reducing 5 
inflammation and disease. However, when monocyte/macrophage accumulation may not be the 6 
primary driver of disease, such as in diabetes, TRAIL-expressing parenchymal cells play a more 7 
prominent role in protection, suggesting a tissue/cell-specific role.  These finding are significant as 8 
they provide important information on which tissue/cells to target in the treatment of atherosclerosis 9 
vs. metabolic diseases dependent on TRAIL signalling. 10 
 11 
In summary, we have identified a unique population of iNOShiTRAIL+ monocyte/macrophages, and 12 
these appear to be potent suppressors of inflammation and atherosclerosis. Furthermore, we suggest 13 
TRAIL is a key modulator of macrophage phenotype and function. Our findings are important 14 
because TRAIL expression is low in monocytes from people with CAD, concomitant with high IL-18 15 
and low TRAIL concentrations in plasma. Importantly, these studies highlight an exciting 16 
immunotherapeutic potential in the treatment of atherosclerosis. Results may spawn wider interest in 17 
the role of this macrophage phenotype in chronic inflammatory conditions.   18 
 19 
LIMITATIONS OF THE STUDY 20 
Atherosclerosis is a multifactorial disease involving other immune cells or their interactions. The 21 
study design did not investigate the effect of TRAIL on other bone marrow originating cells including 22 
neutrophils, T cells and B cells implicated in plaque progression, or their interaction with 23 
monocyte/macrophages. Further, our investigations into the cause of TRAIL suppression focused only 24 
on IL-18, yet due to the complex nature of atherosclerosis, other factors are also likely to contribute.   25 
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FIGURE LEGENDS 1 
Figure 1. Circulating TRAIL is reduced in CAD patients, associating with reduced monocyte TRAIL 2 
mRNA. Blood from the coronary sinus, aortic root (arterial) and lower right atrium (venous) were 3 
collected and assayed for (a) TRAIL and (b) TNF-α by ELISA. (c) The coronary sinus-arterial TRAIL 4 
gradient. Patient samples are n=8-15/group. Venous blood was collected from healthy controls (n=7) 5 
and a second cohort of CAD patients (n=11) and assayed for (d) plasma TRAIL and (e) monocyte 6 
TRAIL gene expression by qPCR. mRNA expression was normalized to GAPDH. One-way ANOVA 7 
or t-test; *p<0.05, **p<0.01, ***p<0.001. 8 
 9 
Figure 2. BM-TRAIL attenuates atherosclerosis. (a) BMT study design. (b) Atherosclerosis is 10 
reduced in BM-TRAIL vs. null- or parenchymal-TRAIL treatment groups. Left, representative H&E 11 
brachiocephalic arteries. Right, quantification of plaque area (n=5-8/group; Scale bar, 20 µm). (c) 12 
Progression of atherosclerosis in Trail-/-Apoe-/- mice in response to a HFD over 12 w. Left, 13 
representative H&E brachiocephalic arteries. Right, quantification of plaque area (n=3-4/group). (d) 14 
Atherosclerosis was reduced in HFD Trail-/-Apoe-/- mice treated with clodronate liposomes. Left, 15 
representative H&E brachiocephalic arteries. Right, quantification of plaque area (n=5-7). (e) BM-16 
TRAIL reduces Mac3+ staining in plaque). Left, Mac3+ staining. Right, quantification of staining. 17 
(n=5-8/group; Scale bar, 20 µm). (f) Aortic TRAIL mRNA expression in BMT mice by qPCR (n=5-18 
8/group). One-way ANOVA or Mann-Whitney U-test; *p<0.05, **p<0.01, ***p<0.001 and 19 
****p<0.0001. 20 
 21 
Figure 3. TRAIL deletion alters cholesterol metabolism in macrophage (a) TRAIL expression in 22 
TRAIL+ve macrophages in response to acLDL for 48 h followed by 16 h equilibration. (b) Scavenger 23 
receptor mRNA expression, (c) phagocytosis of beads and (d) mRNA expression of cholesterol 24 
transporters ABCA1, ABCG1 and SRB1 in basal macrophages. (e) Cholesterol efflux is impaired 25 
with TRAIL deletion, where cells were 3H-acLDL loaded for 48 h, followed by 16 h equilibration and 26 
efflux to ApoA1 for 4 h. (n=3/group). t-test; **p<0.01 and ***p<0.001. 27 
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 1 
Figure 4. TRAIL deletion alters macrophage phenotype and function. 2 
(a) CCL-2 expression in TRAIL+ve vs. TRAIL-ve macrophages. Inflammatory cytokine expression 3 
in macrophages in response to (b) LPS (20 ng/ml) challenge for 24 h or (c) acLDL loading for 48 h 4 
followed by 16 h equilibration. (d) CD11b mRNA expression in basal macrophages and (e) flow 5 
cytometry analysis of CD11b+F4/80+ macrophages. Macrophage (f) cell counts after 7 days 6 
differentiation and (g) apoptosis determined by Annexin V staining after 7, 14 and 21 days 7 
differentiation. (h) MerTK mRNA expression and (i) efferocytosis in macrophages. (i) Migration of 8 
macrophages to CCL-19, in a Transwell assay mRNA was normalized to β-actin. n=3/group; t-test; 9 
*p<0.05. 10 
 11 
Figure 5. TRAIL deletion impairs NO signaling. (a) nitrate/nitrite in plasma from 12 w HFD Apoe-12 
/-
 and Trail-/-Apoe-/- mice (n=7-8/group). (b) Citrulline levels in plasma from BMT mice. Metabolite 13 
peaks were quantified as area under the curve (n=5-8/group). (c) Hierarchical clustering of 845 14 
differentially expressed genes showing opposing gene expression patterns and (d) Gene ontology 15 
(GO) enrichment analysis. Analyses were performed as described in the methods. (e) iNOS mRNA 16 
expression in TRAIL+ve vs. TRAIL-ve macrophages, (f) after 20 ng/ml LPS stimulation for 24 h, or 17 
(g) after acLDL loading for 48 h followed by 16 h equilibration (n=3). iNOS mRNA expression in 18 
aortic tissues from (h) 6 w wildtype vs. Trail-/- mice (6-7/group), (i) 12 w HFD Apoe-/- vs. Trail-/-Apoe-19 
/-
 and (j) from null-, BM- and parenchymal-TRAIL mice (n=5-6/group). mRNA expression was 20 
normalized to β-actin. One-way ANOVA, t-test or Mann-Whitney U-test; *p<0.05, **p<0.01, 21 
***p<0.001 and p<0.0001. 22 
 23 
Figure 6. IL-18 represses TRAIL expression in monocytes. (a) Spearman’s correlation between 24 
plasma TRAIL and IL-18, IL-1β and IL-6. (b) Aortic IL-18 mRNA expression in 12 w HFD Apoe-/- 25 
and Trail-/-Apoe-/- (n=5-7). Monocytes were isolated from healthy donors and treated with 26 
recombinant human IL-18 (30 ng/ml) for 24 h followed by assessment of (c) TRAIL, (d) TNF-α (e) 27 
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NFκB p65 and (f) Sp1 mRNA expression measured by qPCR (n=3). (g) IL-18 (30 ng/ml) represses 1 
NFκB p-p65 protein expression as assessed by Western blotting, quantification on right (n=3) (h) IL-2 
18 (30 ng/ml) reduces NFκB enrichment on the endogenous TRAIL promoter, but Sp1 enrichment 3 
remained unaltered. All mRNA expression was normalized to β-actin or GAPDH. One-way ANOVA 4 
or t-test; *p<0.05 and **p<0.01. 5 
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TABLES 1 
 2 
Table 1: Body weight and plasma chemistries from bone marrow chimera mice 3 
  Null BM Parenchymal 
Body weight (g) 28.38 ± 1.9 27.20 ± 0.8 28.17 ± 0.7 
Glucose (mmol/L)  7.58 ± 0.8 7.16 ± 0.6 8.98 ± 0.3 
Insulin (pmol/L)  44.87 ± 3.2 37.73 ± 2.1 40.75 ± 2.8 
Cholesterol (mmol/L)  18.04 ± 3.3 19.28 ± 2.4 21.95 ± 5.9 
Triglycerides (mmol/L)  2.29 ± 0.3 1.99 ± 0.3 1.96 ± 0.5 
TRAIL (pg/ml)  0 810.7 ± 108.2 1966 ± 503.5* 
 4 
Plasma chemistries from null-, BM and parenchymal-TRAIL mice at euthanasia (n=5-8/group). One-5 
way ANOVA; *p < 0.05 vs. BM. 6 
 7 
 8 
  9 
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Table 2. Metabolomic changes in 6 w old Trail-/- vs. wildtype plasma.  1 
 
Metabolite 
 
Wildtype 
 
Trail-/- 
ADMA 0.4932 ± 0.1219 0.3556 ± 0.08856 
Arginine 0.7568 ± .09599 0.5087 ± 0.04466** 
Citrulline 0.1864 ± 0.0275 0.1483 ± 0.006803* 
Cysteine 2.097 ± 0.1294 1.164 ± 0.1087** 
Methionine 0.8381 ± .04502 0.7719 ± 0.1206 
 2 
Metabolite peaks quantified as area under the curve. Results are Mean ± SD (n=6); *p<0.05, 3 
**p<0.01. 4 
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Highlights 
• Monocytes are a significant source of TRAIL in the normal circulation  
• Monocyte TRAIL expression is reduced, concomitant with plasma levels in CAD 
• TRAIL-expressing monocyte/macrophages attenuate atherosclerosis  
• Macrophages lacking TRAIL are dysfunctional 
 
eTOC 
Circulating TRAIL levels are reduced in cardiovascular disease (CVD) patients, implying a protective 
role.  How TRAIL protects against CVD is unclear. Cartland et al. showed that monocytes are a 
significant source of TRAIL, which is reduced in CVD. Further, monocyte/macrophages-expressing 
TRAIL inhibited macrophage infiltration and attenuated atherosclerosis in mice.   
